By Nigam Arora & Dr. Natasha Arora
To gain an edge, this is what you need to know now.
Editor’s note: This column was first published for paid subscribers on October 21, 2021. At that time, Trump SPAC was trading at $47. Since the first publication, Trump’s SPAC has traded as high as $175.
Trump SPAC Excitement
Please click here for a chart of Nasdaq 100 ETF (QQQ).
Note the following:
- There is a change in guidance. Please see the ‘Buy Zones And Buy Now Ratings’ below.
- You may recall when the meme crowd got excited about GameStop (GME), a brick and mortar retailer of video games, and pushed the stock from under $10 to $483.
- The meme crowd believes they have found the next GME in the Trump SPAC (DWAC). DWAC is up 371% for the day as of this writing and trading at $47. The meme crowd is cheering on everyone to buy DWAC to run it to $500.
- Trump Media & Technology Group plans to merge with DWAC. Trump Media’s new social network will be called TRUTH Social. It will rival FB, TWTR, and GOOG. If that was not enough, the company will also offer subscription programming and rival NFLX as well as Disney+.
- Bulls are already excited to run the stock market to new highs. Trump SPAC is like spiking the punch.
- This is not good news for Fox (FOXA). A signal will be published shortly in ZYX Short.
- The chart shows steady buying.
- The VUD indicator is the most sensitive measure of net supply demand in real-time. The orange represents net supply and the green represents net demand.
- The chart shows the VUD indicator is mostly green.
Leading Indicator
Leading Indicators came at 0.2% vs. 0.5% consensus. This is the 17th month in a row that leading indicators are positive.
Existing Home Sales
Existing Home Sales came at 6.29M vs. 6.05M consensus.
Money Flows
The momo crowd money flows since the Morning Capsule are 🔒 (To see the locked content, please take a 30 day free trial).
Smart money flows since the Morning Capsule are 🔒.
Short squeeze money flows are 🔒.
A Special Note To New Subscribers
Note the smart money behavior. Smart money tends to sell into strength on strong up days.
New subscribers should consider adopting smart money’s way of investing and trading.
Sentiment
Sentiment is 🔒.
Sentiment is a contrary indicator at extremes. In plain English, this means that when sentiment becomes extremely positive it is time to sell and when sentiment becomes extremely negative it is time to buy.
Gold
The momo crowd money flows in gold are 🔒 since the Morning Capsule.
Smart money flows are🔒 in gold since the Morning Capsule.
Oil
The momo crowd money flows in oil are🔒 since the Morning Capsule.
Smart money flows in oil are 🔒 since the Morning Capsule.
Buy Zones And Buy Now Ratings
🔒
Nibbling
🔒
Close
There appear to be buy on close orders.
There is merit to watching the pattern of market on close orders as they represent the day’s dominant net cumulative activity by many professionals and funds.
This post was published yesterday in The Arora Report paid services. Since then the Morning Capsule has had an update in the paid services.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE THE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
